Kinetics of the bile acid transporter and hepatitis B virus receptor Na+/taurocholate cotransporting polypeptide (NTCP) in hepatocytes

Journal of Hepatology

Volumn 61, Issue 4, 2014, Pages 867-875

  König, Alexander ^a,b   Döring, Barbara ^a   Mohr, Christina ^a,b   Geipel, Andreas ^a,b   Geyer, Joachim ^a   Glebe, Dieter ^a,b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b German Center for Infection Research (DZIF)   (Germany)

Author keywords

ASBT; Bile acids; Ezetimibe; Hepatitis B virus; Infection; NTCP; Receptor; SOAT; Therapy; Transport

Indexed keywords

BILE ACID; EZETIMIBE; GLYCOCHENODEOXYCHOLIC ACID; MEMBRANE PROTEIN; PEPTIDE; PROTEIN MYR PRES1; SODIUM BILE ACID COTRANSPORTER; TAURINE; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; VIRUS PROTEIN; VIRUS RECEPTOR; BILE ACID BINDING PROTEINS; CARRIER PROTEIN; COTRANSPORTER; ORGANIC ANION TRANSPORTER; SODIUM-BILE ACID COTRANSPORTER;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HEK293 CELL LINE; HEPATITIS B; HEPATITIS B VIRUS; HEPG2 CELL LINE; HUMAN; HUMAN CELL; LIVER CELL; MYRISTYLATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SCANDENTIA; TUPAIA BELANGERI; ANIMAL; METABOLISM; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL; VIROLOGY; VIRUS ENTRY;

ANIMALS; BILE ACIDS AND SALTS; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; HEP G2 CELLS; HEPATITIS B; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; MEMBRANE GLYCOPROTEINS; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; SYMPORTERS; TUPAIA; VIRAL PROTEINS; VIRUS INTERNALIZATION;

EID: 84926407504     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.05.018     Document Type: Article

References (26)

1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30: 2212-2219.
2. Drexler JF, Geipel A, König A, Corman VM, van RD, Leijten LM, et al. Bats carry pathogenic hepadnaviruses antigenically related to hepatitis B virus and capable of infecting human hepatocytes. Proc Natl Acad Sci U S A 2013; 110: 16151-16156.
3. Glebe D, Urban S, Knoop EV, Cag N, Krass P, Grün S, et al. Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes. Gastroenterology 2005; 129: 234-245.
4. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 2012; 1: e00049.
5. Geyer J, Wilke T, Petzinger E. The solute carrier family SLC10: more than a family of bile acid transporters regarding function and phylogenetic relationships. Naunyn Schmiedebergs Arch Pharmacol 2006; 372: 413-431.
6. Stieger B. The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation. Handb Exp Pharmacol 2011: 205-259.
7. Döring B, Lütteke T, Geyer J, Petzinger E. The SLC10 carrier family: transport functions and molecular structure. Curr Top Membr 2012; 70: 105-168.
8. Geyer J, Döring B, Meerkamp K, Ugele B, Bakhiya N, Fernandes CF, et al. Cloning and functional characterization of human sodium-dependent organic anion transporter (SLC10A6). J Biol Chem 2007; 282: 19728-19741.
9. Sureau C, Salisse J. A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinant. Hepatology 2013; 57: 985-994.
10. Leistner CM, Gruen-Bernhard S, Glebe D. Role of glycosaminoglycans for binding and infection of hepatitis B virus. Cell Microbiol 2008; 10: 122-133.
11. Yan H, Peng B, He W, Zhong G, Qi Y, Ren B, et al. Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide. J Virol 2013; 87: 7977-7991.
12. Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Fälth M, et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 2013; 146: 1070-1083.
13. Yan H, Peng B, Liu Y, Xu G, He W, Ren B, et al. Viral entry of Hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide. J Virol 2014; 88: 3273-3284.
14. Glebe D, Aliakbari M, Krass P, Knoop EV, Valerius KP, Gerlich WH. Pre-s1 antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virus. J Virol 2003; 77: 9511-9521.
15. Köck J, Nassal M, MacNelly S, Baumert TF, Blum HE, von Weizsäcker F, et al. Efficient infection of primary tupaia hepatocytes with purified human and woolly monkey hepatitis B virus. J Virol 2001; 75: 5084-5089.
16. Mühlfeld S, Domanova O, Berlage T, Stross C, Helmer A, Keitel V, et al. Shortterm feedback regulation of bile salt uptake by bile salts in rodent liver. Hepatology 2012; 56: 2387-2397.
17. Liang D, Hagenbuch B, Stieger B, Meier PJ. Parallel decrease of Na(+)- taurocholate cotransport and its encoding mRNA in primary cultures of rat hepatocytes. Hepatology 1993; 18: 1162-1166.
18. Watashi K, Sluder A, Daito T, Matsunaga S, Ryo A, Nagamori S, et al. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter NTCP. Hepatology 2014; 59: 1726-1737.
19. Nkongolo S, Ni Y, Lempp FA, Kaufman C, Lindner T, Esser-Nobis K, et al. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilinindependent interference with the NTCP receptor. J Hepatol 2013; 164: 1070-1083.
20. Poupon R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol 2012; 36: S3-S12.
21. Dilger K, Hohenester S, Winkler-Budenhofer U, Bastiaansen BA, Schaap FG, Rust C, et al. Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health. J Hepatol 2012; 57: 133-140.
22. Chen W, Liu J, Gluud C. Bile acids for viral hepatitis. Cochrane Database Syst Rev 2007; 4: CD003181.
23. Schieck A, Schulze A, Gähler C, Müller T, Haberkorn U, Alexandrov A, et al. Hepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hosts. Hepatology 2013; 58: 43-53.
24. Kim RB, Leake B, Cvetkovic M, Roden MM, Nadeau J, Walubo A, et al. Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity. J Pharmacol Exp Ther 1999; 291: 1204-1209.
25. Dong Z, Ekins S, Polli JE. Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP). Mol Pharm 2013; 10: 1008-1019.
26. Suchy D, Labuzek K, Stadnicki A, Okopien B. Ezetimibe - A new approach in hypercholesterolemia management. Pharmacol Rep 2011; 63: 1335-1348.